

Antibiotic Susceptibility and Carbapenem Resistance of Gram Negative Bacilli Recovered from Various Specimens of Hospitalized Patients in a Training Hospital for Chest Diseases (*)

Can BİÇMEN (**), Güneş ŞENOL (**), Fatma Nur ERİŞ (**), Nermin FLORAT (**)

(*) 11. " European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) " ' de (1-4 Nisan 2001, İstanbul) poster olarak sunulmuştur.

(**) İzmir Göğüs Hastalıkları ve Cerrahisi Eğitim ve Araştırma Hastanesi, Mikrobiyoloji Laboratuvarı, İzmir

ÖZET

Bir Göğüs Hastalıkları Eğitim Hastanesinde Yatan Hastaların Çeşitli Örneklerinden Soyutlanan Gram Negatif Çomakların Antibiyotiklere Duyarlılıkları ve Karbapeneme Direnç Özellikleri

Bu çalışmada, İzmir Göğüs Hastalıkları Hastanesinde Ekim-Kasım 2000 aylarında izole edilen 44 *Pseudomonas* spp., 9 *Klebsiella*, 8 *Escherichia coli*, 6 *Enterobacter*, 4 *Acinetobacter*, 3 Gram olumsuz nonfermentatif çomak ve bir *Proteus mirabilis* suşu olmak üzere toplam 75 suş incelenmiştir. *Pseudomonas* ve *Acinetobacter* suşlarının dışında kalan suşların amoksisilin-klavulanik asite (AMC) direnç oranları ortalama % 30 olarak bulunmuştur. Oksimino-beta laktamlara dirençli suşların oranı ortalama % 41-52 olarak saptanmıştır. *Pseudomonas*, *Klebsiella* ve *Enterobacter* suşlarında genişlemiş spektrumlu beta-laktamaz oluşumu, sırasıyla, 12 / 44 (% 27.2), 1 / 9 (% 11.1) ve 3 / 6 (% 50) oranlarında belirtilmiştir. Direkt induksiyon testi ile *Pseudomonas* ve *Enterobacter* suşlarında induklenebilir beta-laktamaz üretimi sırasıyla 15 / 44 (% 34), 1 / 6 (% 16.6) oranlarında gösterilmiştir. Disk difüzyon testi ile karbapeneme direnç, imipenem için suşların 18'inde (% 24), meropenem için ise 16'sında (% 21.3) saptanmıştır. İmipeneme disk difüzyon ile orta derecede duyarlı bulunan bir *Acinetobacter* ve bir *Pseudomonas* suşu, meropeneme karşı duyarlı bulunmuştur. Genel olarak, MİK değerlerine göre, Gram olumsuz nonfermentatif çomaklarda imipeneme direnç, meropeneme göre anlamlı derecede yüksek bulunmuştur ($p < 0.05$). Bunun yanı sıra, meropenem için disk difüzyon ile bulunan direnç oranları, MİK değerlerine göre bulunan oranlardan anlamlı derecede yüksek bulunmuştur ($p < 0.05$).

Anahtar kelimeler: Gram olumsuz çomak, antibiyotiklere duyarlılık, genişlemiş spektrumlu beta-laktamaz, induklenebilir beta-laktamaz, karbapenemler, direnç.

SUMMARY

In this study, a total of 75 gram negative rods, comprising 44 *Pseudomonas* spp., 9 *Klebsiella* spp., 8 *Escherichia coli*, 6 *Enterobacter* spp., 4 *Acinetobacter* spp., 3 Gram negative nonfermentative bacilli and one *Proteus mirabilis*, which were isolated at the Training Hospital for Chest Diseases in Izmir during September-October were studied. Amoxicillin-clavulanic acid resistance for the bacteria out of *Pseudomonas* and *Acinetobacter* strains were found as approximately 30 % and for oxyimino beta-lactams as 41-52 %. Ratios for extended spectrum beta-lactamase production which was determined in *Pseudomonas*, *Klebsiella* and *Enterobacter* strains were 12 / 44 (27.2 %), 1 / 9 (11.1 %) and 3 / 6 (50 %), respectively. Inducible beta-lactamase production in *Pseudomonas* and *Enterobacter* strains by direct induction test was determined as the ratios ; 15 / 44 (34 %), 1 / 6 (16.6 %) respectively. Resistance for carbapenems by disk diffusion was found in 18 (24 %) strains for imipenem and in 16 (21.3 %) strains for meropenem respectively. One *Acinetobacter* and one *Pseudomonas* which were found as intermediately resistant against imipenem were determined as susceptible to meropenem. In general, according to the MIC values, imipenem resistance in gram negative nonfermentative rods was significantly higher than meropenem resistance ($p < 0.05$). Moreover, ratio of resistant strains for meropenem by disk diffusion was significantly higher than the ratio according to the MIC values ($p < 0.05$).

Key words : Gram negative rod, antibiotic susceptibility, extended spectrum beta-lactamase, inducible beta-lactamase, carbapenems, resistance.

INTRODUCTION

Antibiotic resistance to Gram negative bacilli in hospital infections is an important problem all over the world and the frequency of resistant strains differs among the hospitals from one region to another. Therefore, it is necessary to follow the surveillance, take the precautions and make the accurate therapeutic selections. The most important gram negative bacilli in hospital infections are *Pseudomonas aeruginosa*, *Escherichia coli*, *Klebsiella spp.*, *Enterobacter spp.*, *Acinetobacter spp.* and *Serratia spp.* Bacterial resistance are mainly due to production of a variety of beta-lactamases (1, 2). Isolates which produce extended spectrum beta-lactamases (ESBL) and/or chromosomally encoded inducible beta-lactamases are widespread and the percentage of their presence differs in different species from hospital to hospital. Additionally, carbapenem resistance which has been increasing in Gram negative bacilli, especially in nonfermentative bacilli such as *Pseudomonas aeruginosa*, *Acinetobacter spp.* and *Stenotrophomonas maltophilia* causes a great problem in hospitalized patients (1). Resistance to carbapenems are mainly due to metallo beta-lactamase activity, deficiency of Opr D protein (outer membrane protein D2) and porin mutations (3-10). In the present study, it was intended to analyze the susceptibility of hospital-acquired Gram negative bacilli to various antibiotics and evaluate their resistance against carbapenems.

MATERIALS AND METHODS

In this study, a total of 75 Gram negative bacilli isolated from various samples of patients hospitalized in internal and surgical wards of chest diseases and intensive care units at the Training and Research Hospital For Chest Diseases and Chest Surgery in Izmir-Turkey during October and November 2000, were analyzed. Distribution of isolation rates of various samples according to the strain species is shown in Table 1. Forty-four isolates were *Pseudomonas spp.*, nine *Klebsiella spp.*, eight *E.coli*, six *Enterobacter spp.*, four *Acinetobacter spp.*, three Gram negative nonfermentative bacilli and one *Proteus mirabilis* (11,12). Susceptibility

patterns of these strains were investigated for meropenem (MEM 10 µg, Oxoid), imipenem (IPM 10 µg, Oxoid), ceftriaxone (CRO 30 µg, Oxoid), ceftazidime (CAZ 30 µg, Oxoid), aztreonam (ATM 30 µg, Oxoid), amoxicillin-clavulanic acid (AMC 20 µg / 10 µg, Oxoid), isepamicin (ISP 30 µg, Oxoid), gentamicin (CN 10 µg, Oxoid), levofloxacin (LEV 5 µg, Oxoid), ciprofloxacin (CIP 5 µg, Oxoid), piperacillin-tazobactam (TZP 75/10 µg, Oxoid) and cefoperazone-sulbactam (SCF 75 / 30 µg, Oxoid) by disk diffusion method on Mueller-Hinton agar according to the recommendations of " National Committee for Clinical Laboratory Standards " (NCCLS) (13). Resistance to all the oxyimino-beta-lactams by disk diffusion method was evaluated as presumptive for ESBL (16-18). Double disk synergy test was used to confirm ESBL and direct induction test was used to define inducible beta-lactamase (14 -16).

Twelve of 18 strains were found as resistant (≤ 13 mm zone) and six as intermediately resistant (14 -15 mm zone) to IPM whereas 10 were resistant, six intermediate and two susceptible to MEM by the disk diffusion method. These strains which appeared to be intermediate and resistant to carbapenems by disk diffusion method were analyzed for MIC levels by agar dilution and microdilution methods for IPM and MEM, respectively. MIC levels of ≥ 16 µg / mL were accepted as resistance to carbapenems; ≤ 4 µg / mL and equivalent to 8 µg / mL (4 µg / mL < MIC < 16 µg / mL) as susceptible and intermediately resistant, respectively.

Statistical Analysis

Comparison of the groups were performed by chi-square test with Yate's correction for statistical analysis. P value less than 0.05 was accepted as statistically significant.

RESULTS

The resistance rates of Gram negative bacilli were found as 14.6 % (n=11) for MEM, 17.3 % (n=13) for IPM, 52 % (n=39) for CRO, 32 % (n=24) for CAZ, 38.6 % (n=29) for ATM, % 33.3 (n=25) for AMC, 26.6 % (n=20) for ISP, 40 % (n=30) for CN, 25.3 % (n=19) for LEV, 20 % (n=15) for CIP, 20 % (n=15)

for TZP and 8 % (n=6) for SCF. When strains which had intermediate level of antibiotic resistance were accepted as resistant, proportions of resistance rates were 16 %, 17 %, 42 %, 31 %, 38 %, 30 %, 26 %, 37 %, 20 %, 20 %, 28 %, 23 % for MEM, IPM, CRO, CAZ, ATM, AMC, ISP, CN, LEV, CIP, TZP and SCF,

respectively. Distribution of antibiotic resistance rates of Gram negative bacilli is shown in Tables 2A and 2B.

Presence of ESBL was indicated in 12 of 44 (27.3 %) *Pseudomonas spp.*, one of nine (11 %) *Klebsiella spp.* and three of six (50 %) *Enterobacter spp.* by

Table 1. Distribution of strains isolated from different samples

Sample	Pseudomonas spp.		Klebsiella spp.		Escherichia coli		Enterobacter spp.		Acinetobacter spp.		Gram Negative Nonfermentative bacilli	
	Male n (%)	Female n (%)	Male n (%)	Female n (%)	Male n (%)	Female n (%)	Male n (%)	Female n (%)	Male n (%)	Female n (%)	Male n (%)	Female n (%)
Biopsy							1 (1.3)					
Wound	15 (20)	11 (14.6)	1 (1.3)									
Sputum			3 (4.0)	1 (1.3)	3 (4)		3 (4.0)	1 (1.3)	1 (1.3)	1 (1.3)	2 (2.6)	
Urine				3 (4.0)		3 (4.0)						
Drenage	7 (9.3)				1 (1.3)						1 (1.3)	
Bronchial aspiration	8 (10.6)	3 (4.0)	1 (1.3)				1 (1.3)		2 (2.6)			
Vaginal						1 (1.3)						
	30 (40)	14 (18.6)	5 (6.6)	4 (5.3)	4 (5.3)	4 (5.3)	5 (6.6)	1 (1.3)	3 (4.0)	1 (1.3)	3 (4.0)	-
Total(n=75)	44 (58.6)		9 (12.0)		8 (10.6)		6 (8.0)		4 (5.3)		3 (4.0)	

Table 2A. Resistance of gram negative bacilli to various antibiotics

Antibiotic	MEM	IPM	CRO	CAZ	ATM	AMC*	ISP	CN	LEV	CIP	TZP	SCF
Resistance rates (%)	14.6	17.3	52	32	38.6	33.3	26.6	40	25.3	20	20	8
(n)	11	13	39	24	29	25	20	30	19	15	15	n=6

* AMC resistance was not taken into account for *Pseudomonas* and *Acinetobacter* strains. For AMC these strains were accepted as resistant.

Table 2B. Resistances* of gram negative bacilli to various antibiotics

Strain	Isolates n (%)	Number and rates of Isolates Resistant to Antibiotics**											
		MEM	IPM	CRO	CAZ	ATM	AMC***	ISP	CN	LEV	CIP	TZP	SCF
Pseudomonas spp.	44(58.6)	13(29.5)	13(29.5)	30(68)	22(50)	26(59)	44(100)	19(43)	24(54.5)	13(29.5)	13 (29.5)	16(36.3)	15(34)
Klebsiella spp.	9 (12)	-	-	1(11)	-	1(11)	1(11)	-	1(11)	-	-	3(33.3)	1(11)
E.coli	8 (10.6)	-	-	2(25)	-	2(25)	1(12.5)	2(25)	4(50)	2(25)	2(25)	1(12.5)	1(12.5)
Enterobacter spp.	6 (8)	1(16.6)	1(16.6)	5(83.3)	5(83.3)	5(83.3)	5(83.3)	2(33.3)	3(50)	2(33.3)	3(50)	4(66.6)	3(50)
Acinetobacter spp.	4 (5.3)	2(50)	3(75)	3(75)	3(75)	3(75)	4(100)	3(75)	3(75)	3(75)	2(50)	3(75)	3(75)
Gram negative nonfermenter	3 (4)	1(33.3)	1(33.3)	1(33.3)	1(33.3)	1(33.3)	1(33.3)	-	1(33.3)	-	-	1(33.3)	-
P.mirabilis	1 (1.3)	-	-	-	-	-	-	-	1(1.3)	-	-	-	-
Total	75(100)	16(21.3)	17(22.6)	42(56)	31(41.3)	38(50.6)	56(74.7)	26(34.6)	37(49.3)	20(26.6)	20(26.6)	28(37.3)	23(30.6)

* Intermediately resistant strains were accepted as resistant.

** AMC resistance against microorganisms out *Pseudomonas spp.* and *Acinetobacter spp.* was found as 8/27 (29.6 %)

double disk synergy test and evaluation of resistance in all oxyimino-beta lactams tested. Inducible beta-lactamase production was determined in 15 of 44 (34 %) *Pseudomonas* spp. and one of six (16.6 %) *Enterobacter* spp. by direct induction test. There was no visible beta-lactamase production in eight *E. coli* and three Gram negative nonfermentative bacilli. *Acinetobacter* strains were not taken into account as their mechanisms of detection of beta-lactamases are not clear enough phenotypically (18). Distribution of beta-lactamases detected in Gram negative bacilli is shown in Table 3.

Eighteen carbapenem-resistant strains of which the susceptibility patterns were analyzed were found as completely (n=12) or intermediately (n=6) resistant to IPM, whereas, 16 of these strains were found as completely (n=10) or intermediately (n=6) resistant

to MEM by disk diffusion method. One *Acinetobacter* spp. and one *Pseudomonas* spp. which were intermediately resistant to IPM were found as susceptible to MEM by disk diffusion method. MIC levels of these strains were MICIPM > 16 µg/mL and MICMEM 2-4 µg/mL for *Acinetobacter* spp. and MICIPM > 16 µg/mL and MICMEM > 8 µg/mL for *Pseudomonas* spp. All the resistant strains to carbapenems which were tested for their MIC levels showed bacterial growth up to 2 µg/ml of drug concentration. Nine of 13 *Pseudomonas* strains were resistant (MIC > 16 µg/mL) and four *Pseudomonas* strains were intermediately resistant (4 µg / mL < MIC < 16 µg / mL) to IPM. Two of four *Acinetobacter* strains were resistant (MIC > 16 µg / mL) and two *Acinetobacter* strains were intermediately resistant (4 µg / mL < MIC < 16 µg /

Table 3. Distribution of beta-lactamases detected in gram negative bacilli.

Strain		ESBL* positive		Inducible beta-lactamase positive	
		n	%	n	%
<i>Pseudomonas</i> spp.	(n=44)	12	(27.2)	15	(34)
<i>Klebsiella</i> spp.	(n=9)	1	(11.1)	1	(11.1)
<i>E.coli</i>	(n=8)	-		-	
<i>Enterobacter</i> spp.	(n=6)	3	(50)	1	(16.6)
<i>Acinetobacter</i> spp.	(n=4)	-		-	
GNF	(n=3)	-		-	

Table 4. Distribution of the MIC levels for meropenem and imipenem.

Strain	MIC (mg/ml)	Number of Isolates Detected For MIC levels	
		IPM (n*=18)	MEM (n**=18)
<i>Pseudomonas</i> spp. (n=13)	2-4		2
	>4	1	4
	>8	3	4
	>16	1	1
	>32	1	
	>64	7	2
	2-4		3
<i>Acinetobacter</i> spp. (n=4)	>4		1
	>8	2	
	>16	2	
	>32		
	>64		
GNF (n=1)	2-4		
	>8		1
	>16		
	>32		
	>64	1	

Abbreviations: GNF : gram negative nonfermentative bacilli

* Twelve of 18 were found as resistant and six of them were found as intermediate by disk diffusion method.

** Ten of 18 were found as resistant, six of them were found as intermediate and two of them were found as susceptible by disk diffusion method.

mL) to IPM. One Gram negative nonfermentative bacillus which needed further identification showed resistance to IPM with the MIC level over 64 $\mu\text{g}/\text{mL}$. These findings had correlation with the results by disk diffusion test for IPM. Three strains among 13 *Pseudomonas spp.* were resistant to MEM according to the MIC levels ($\text{MIC} > 16 \mu\text{g} / \text{mL}$) and eight of them were intermediately resistant ($4 \mu\text{g} / \text{mL} < \text{MIC} < 16 \mu\text{g} / \text{mL}$) and two of them which had $2 \mu\text{g} / \text{mL} < \text{MIC} < 4 \mu\text{g} / \text{mL}$ of MIC levels were accepted as susceptible to MEM. One of four *Acinetobacter* strains were intermediately resistant ($4 \mu\text{g} / \text{mL} < \text{MIC} < 16 \mu\text{g} / \text{mL}$) and three of them which had $2 \mu\text{g} / \text{mL} < \text{MIC} < 4 \mu\text{g} / \text{mL}$ of MIC levels were accepted as susceptible to MEM. One Gram negative nonfermentative bacillus was intermediately resistant ($4 \mu\text{g} / \text{mL} < \text{MIC} < 16 \mu\text{g} / \text{mL}$) to MEM. These findings didn't have correlation with the disk diffusion test. Ten strains were completely resistant to MEM by disk diffusion method when three strains were found as completely resistant according to the MIC levels. Six strains were found as intermediately resistant to MEM by disk diffusion method whereas 10 strains were found as intermediately resistant to MEM and five strains were susceptible to MEM according to the MIC levels ($2\text{-}4 \mu\text{g} / \text{mL}$). Two strains were susceptible to MEM and intermediately resistant to IPM by disk diffusion method and MIC levels of these two strains were $\text{MIC}_{\text{IPM}} > 16 \mu\text{g} / \text{mL}$ and $\text{MIC}_{\text{MEM}} 2\text{-}4 \mu\text{g} / \text{mL}$ for an *Acinetobacter* strain and $\text{MIC}_{\text{IPM}} > 16 \mu\text{g} / \text{mL}$ and $\text{MIC}_{\text{MEM}} > 8 \mu\text{g} / \text{mL}$ for a *Pseudomonas* strain. Distribution of the MIC levels of the strains for MEM and IPM is shown in Table 4.

In general, it was found that IPM resistance among Gram negative nonfermentative bacilli was statistically higher than MEM according to the MIC levels ($p < 0.05$). Moreover, resistance rates for MEM which were found by disk diffusion method were statistically higher than the ones according to the MIC levels ($p < 0.05$).

DISCUSSION

Antibiotic resistance against Gram negative bacilli has been studied so many times in previous reports (5,6,20-26). Investigation of beta-lactamase

production has been carried out by different methods with modifications and different results have been taken (14,17,21,27). In the present study, total of beta-lactamase producing strains were found as 22.5 %. Four *Acinetobacter* strains were not taken into account as the phenotypical detection of beta-lactamase production in *Acinetobacter* strains has not been defined clearly (28).

In a study from Hungary (21) in the year of 2000 which has been made in approximately 3500 *Enterobacteriaceae*, resistance to AMC was 11-45 % whereas resistance to third generation cephalosporins in *E. coli*, *Klebsiella-Enterobacter*, *Proteus-Providencia-Morganella* was 3-8 %, 15-52 %, 16-27 % respectively. In the present study, AMC resistance against gram negative bacilli out of *Acinetobacter* and *Pseudomonas* strains was ~ 30 % and resistance to third generation cephalosporins was found as 41-56 %. In the same study from Hungary, isoelectric points, inhibitor profiles and substrate profiles have been analyzed and it has been thought that the resistance was mainly due to the hyperproduction of chromosomally encoded AmpC beta-lactamases.

In most of the strains which were found as ESBL positive by double disk synergy or resistance to all oxyimino beta-lactams, AMC resistance was observed as well suggesting that resistance against beta-lactamase inhibitors occurs mainly by the mechanisms: hyperproduction of beta-lactamases, production of beta-lactamases resistant to inhibitors and chromosomal cephalosporinases (2,28,29).

Various mechanisms and beta-lactamases might play a role in the occurrence of multiple resistant strains. This may address the issue that inducible beta-lactamase production could be in higher rates than the amounts which were determined by direct induction test, especially in *Pseudomonas* strains. Practically, it is accepted that *Enterobacter cloacae*, *Pseudomonas aeruginosa* and *Acinetobacter spp.* always produce chromosomally inducible beta-lactamases at a certain level (30).

In a study from Brasil (25) in 2000, 608 gram negative isolates have been analyzed and identified as *Pseudomonas aeruginosa* (20 %), *E. coli* (17 %),

Acinetobacter spp. (16 %) most frequently. High level of resistance against all beta-lactams tested has been found in *Pseudomonas* strains. In the present study, resistance rates were higher in Gram negative nonfermentative bacilli and *Pseudomonas* strains (n=44) were identified most frequently (58.6 %) among them. Resistance and intermediate resistance for IPM were observed in nine and four of 13 *Pseudomonas* strains, respectively, whereas three and eight of 13 were found as completely and intermediately resistant to MEM according to the MIC levels. In addition with these, two *Pseudomonas* isolates were found as susceptible (2-4 µg/ml) for MEM according to the MIC levels. In *Acinetobacter* strains, two of them were resistant and two were intermediately resistant to IPM. Three of them were susceptible and one of them were intermediately resistant to MEM according to the MIC levels.

In studies from U.S.A (23,31) in 2000 and 2001, which included a surveillance program in 1998 in the patients with the diagnosis of pneumonia, the most frequent strains were *P. aeruginosa* (26.8 %), *S. aureus* (24 %), *Klebsiella* spp. (12.1 %) and *Acinetobacter* spp. (10.5 %). In the present study, the most frequent strains isolated were *Pseudomonas* spp. (58.6 %), *Klebsiella* spp. (12 %), *E.coli* (10.6 %), *Enterobacter* spp. (8 %), *Acinetobacter* spp. (5.3 %), other Gram negative nonfermenter bacilli (4 %) and *Proteus mirabilis* (1.3 %). Gram negative strains especially *Pseudomonas* spp. and *Acinetobacter* spp. have showed high resistance rates against the agents tested in these studies. In our hospital, Gram negative nonfermentative bacilli have been isolated most frequently as compared with other strains.

In recent years, *Paeruginosa* strains producing plasmid-mediated ESBL have been reported increasingly (1,2,4,32). Most of them are non-SHV and non-TEM type of ESBLs such as; PER-1, IMP-1 and OXA type (33,34). Besides these, *Acinetobacter* strains have ARI-type enzymes which lead to clonal spread (33). Some SHV and TEM type of ESBLs in *Pseudomonas aeruginosa* from different countries such as Thailand and France have been reported in recent years (32,35).

In some studies reported from Turkey, ESBL positivity has been found 20-90 % in *Klebsiella* spp., 10 % in *P. aeruginosa*, 50 % in *Acinetobacter* spp. SHV type of ESBL in *Klebsiella* spp. and PER-1 in *Pseudomonas* spp. and *Acinetobacter* spp. are seen most frequently (27,28). In a study from Turkey (27) in 1999, ESBL positivity has been found as 30 % and inducible beta-lactamase production has been reported as 29 %. Inducible beta-lactamase production have been found in nine of 17 *Pseudomonas* strains and only seven of them have been designated by direct induction test. In 1998, in a multi-center study which has been carried out in Turkey, ESBLs have been found as 33-86 % in *Klebsiella* spp. and 0-27 % in *E.coli* (2). In the present study, ESBL and inducible beta-lactamase production were found as 27 % and 34 % in *Pseudomonas* spp. (n=44) and 50 % and 16.6 % in *Enterobacter* spp. (n=6) respectively. ESBL production was found as 11 % in *Klebsiella* spp. (n=9). ESBL was not determined in *E. coli* (n=8) strains. These results address the issue that beta-lactamase production have shown different frequencies in different studies.

Pseudomonas aeruginosa produces inducible AmpC enzyme (chromosomal B lactamase Group 1 Class C) like *Enterobacter* spp. as well. This is one of the reasons for the occurrence of the resistant strains against beta-lactamase inhibitors. Hyperproduction of TEM enzyme, class B, C, and D enzymes resistant to inhibitors, loss of porins in addition to the classical beta-lactamases, mutants of TEM enzymes resistant to inhibitors are the reasons for the resistance against beta-lactamase inhibitors (4, 5, 7,10, 28, 29, 32, 36).

Increasing levels of carbapenem resistance have been being reported especially in *Pseudomonas aeruginosa* and *Acinetobacter* spp. in recent years (20, 37, 38). Mono or multi-resistant strains in *Pseudomonas* spp. have been occurring by means of porin-efflux system and chromosomal beta-lactamases. Resistance to carbapenems during therapy occurs frequently. Porin mutations and carbapenemases cause carbapenem resistance (5,6). In a study from Izmir-Turkey (3), carbapenem

resistance (and its mechanisms) have been reported as 92 %, 60 % and 100 % in *Acinetobacter baumannii*, *P.aeruginosa* and *S. maltophilia*, respectively. In another study from Ankara-Turkey (24), MEM resistance has been reported as 2 % and 0 % for MEM and IPM in *Klebsiella* spp. respectively. In the same study, resistance for MEM and IPM in *P.aeruginosa* have been reported as 4 % and 21 % respectively and there was no resistance among *E.coli*, *Proteus* and *Enterobacter* strains. In two reports from Turkey , carbapenem resistance in *P.aeruginosa* has been found as 33 % and 17-18 % and as 23.8 % in *Acinetobacter* spp. (20,22,27). In intensive care units, carbapenem resistance is much higher than usual and it has been reported as 66 % and 53 % for IPM and MEM respectively (38). In the present study, MEM and IPM resistance were found as 14.6 % and 17.3 % and if intermediately resistant strains were accepted as resistant, the resistance rates were 17 % and 18 % for MEM and IPM, respectively. Carbapenem resistance for both MEM and IPM was 27 % in *Pseudomonas* spp. including *P. aeruginosa*. There were carbapenem resistance in one of six *Enterobacter* spp., in two of four *Acinetobacter* against MEM and three of four *Acinetobacter* strains against IPM respectively and in one Gram negative nonfermenter bacillus against both MEM and IPM. When we searched for their MIC levels, higher concentrations of MIC levels were observed for IPM than the MIC levels for MEM in *Pseudomonas* spp. (n=13), *Acinetobacter* spp. (n=4) and in one gram negative nonfermenter bacillus. In the present study, there were no resistance to carbapenems in *Klebsiella* spp., *E.coli*, *Enterobacter* spp. and in one *P. mirabilis* which were taken into the study. Carbapenem resistance in gram negative nonfermentative bacilli have been reported from Turkey and other countries. In some of these studies, *Pseudomonas* strains have been found as more susceptible to MEM than IPM and there have been studies reporting IPM as more susceptible (22, 24, 25, 37). In the present study, there was no significant difference between MEM and IPM activities by disk diffusion method. But the MIC levels of MEM were in lower concentrations than the MIC level concentrations of IPM as well.

In conclusion, increasing production of beta-lactamases and resistance levels against carbapenems in gram negative bacilli especially in gram negative nonfermentative bacilli isolated from internal and surgical units and especially from the intensive care units indicates the widespread use of those antibiotics that leads to selection of resistant organisms and an endemic problem in some hospitals in different regions all over the world (25,28,38).

References

1. **Vahaboğlu H** : Çoğul dirençli nonfermentatif gram-negatif basiller. *Hast İnfeks Derg* 4: 222 (2000).
2. **Gür D**: Hastane infeksiyonları ve antimikrobiyal ilaçlara çoğul dirençli gram negatif bakteriler. *Hast İnfeks Derg* 4: 218 (2000).
3. **Gülay Z, Atay T, Yuluğ N** : Gram negatif nonfermentatif çomaklarda karbapenemlere etkili beta-laktamazlar. *ANKEM Derg* 12: 509 (1998).
4. **Gür D**: Beta-laktamazlar, *Flora Ek* 3 (1997).
5. Kaygusuz A, Öngen B, Gürler N, Töreci K: İmipenem dirençli *Pseudomonas* suşlarında saptanan direnç mekanizmaları. *ANKEM Derg* 11 (1997).
6. **Martinez-Martinez L, Pascual A, Hernandez-Alles S et al** : Roles of beta-lactamases and porins in activities of carbapenems and cephalosporins against *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 43: 1669 (1999).
7. **Pai H, Kim J, Lee HJ, Kong WC, Gotoh N**: Carbapenem resistance mechanisms in *Pseudomonas aeruginosa* clinical isolates. *Antimicrob Agents Chemother* 45 : 480 (2001).
8. **Yigit H, Queenan AM, Anderson GJ, Dominech-Sanchez A, Biddle JW, Steward CD, Alberti S, Bush K, Tenover FC**: Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 45 : 1151 (2001).
9. **Yano H, Kuga A, Okamoto R , Kitasato H, Kobayashi T, Inoue M** : plasmid-encoded metallo-beta-lactamase (IMP-6) conferring resistance to carbapenems, especially meropenem *Antimicrob Agents Chemother* 45: 1343 (2001).
10. **Okamoto K, Gotok N, Nishino T**: *Pseudomonas aeruginosa* reveals high intrinsic resistance to penem antibiotics: penem resistance mechanisms and their interplay. *Antimicrob Agents Chemother* 45 : 1964 (2001).
11. **Koneman EW, Allen SD, Janda WM, Schreckenberger PC, Winn WC**: *Color Atlas and Textbook of Diagnostic Microbiology*, p105, 4 th ed. , JB Lippincott Co, Philadelphia (1992).

12. **Koneman EW, Allen SD, Janda WM, Schreckenberger PC, Winn WC:** Color Atlas and Textbook of Diagnostic Microbiology, p185, 4th ed. , JB Lippincott Co, Philadelphia (1992).
13. **NCCLS:** National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests, 6th ed, Approved Standart NCCLS Document M2 A6 (1997).
14. **Akata F:** Gram negatif bakterilerde beta-laktamaz tipleri ve antibiyogramdan beta-laktamaz tipini tahmin etmede kullanılabilecek yöntemler. İnfek Derg 11: 303 (1997).
15. **Sirot J:** Detection of extended spectrum plasmid mediated beta lactamases by disk diffusion. Clin Microbiol Infect 2 (suppl 11): 35 (1996).
16. **Swenson JM, Hindler JA, Peterson LR :** Special Tests for Detecting Antibacterial Resistance, Section X , Chapter 116. “ P R Murray, E J Baron, M A Pfaller, F C Tenover, R H Tenover (eds): Manual of Clinical Microbiology “ , p1361, ASM Press, Washington, D.C. (1995).
17. **Gülay Z, Biçmen Küçüküven M, Yuluğ N:** Genişletilmiş spektrumlu beta laktamaz varlığının saptanmasında kullanılan çeşitli yöntemlerin değerlendirilmesi. ANKEM Derg 12: 514 (1998).
18. **Vahaboğlu H:** Beta-laktamaz tanı testlerinin rutin kullanımı ve klinik önemi. Flora 3: 73 (1998).
19. **Vahapoğlu H, Öztürk R, Aygün G, Coşkun F, Yaman A, Kaygusuz A, Leblebicioğlu H, Balık I, Aydın K, Otkun M:** Widespread detection of PER-1 type extended spectrum B-lactamases among nasocomial Acinetobacter and P. aeruginosa isolates in Turkey ; a nationwide multicenter study. Antimicrob Agents Chemother 41 : 2265 (1997).
20. **Ağaç E, Rastgeldi A, Savaş L, Şimşek F, Dinç E, Yıldırım T:** Acinetobacter suşlarının antibiyotik duyarlılıklarının değerlendirilmesi, 9. Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Kongresi. Özet Kitabı (1999).
21. **Gal Z, Szabo D, Kovacs P, Hernadi F, Toth-Martinez B, Rozgonyi F:** Beta-lactam susceptibility patterns and investigation of cephalosporin hydrolysing beta-lactamases of gram negative extraintestinal clinical isolates. Int J Antimicrob Agents 16 : 395 (2000).
22. **Kılıç D, Kuzucu Ç, Erdinç FÇ, Tülek N, Acar N:** Hastane infeksiyon etkeni olan suşların antibiyotik duyarlılıkları. 9. Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Kongresi, Özet Kitabı (1999).
23. **Lewis MT, Gales AC, Sader HS, Pfaller MA, Jones RN:** Frequency of occurrence and antimicrobial susceptibility patterns for pathogens isolated from latin american patients with a diagnosis of pneumoniae : results from th SENTRY antimicrobial surveillance program (1998). Diagn Microbiol Infect Dis 37: 63 (2000).
24. **Özalp M, Gür D:** Çeşitli gram negatif bakterilere karşı meropenem, imipenem, sefotaksim ve seftazidimin in vitro etkileri, VIII. Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Kongresi, Özet Kitabı (1997).
25. **Özgenç O, Urbarlı A, Erdenizmenli M, Fidan I N, Arı A:** Pseudomonas aeruginosa izolatlarının çeşitli antimikrobiklere direnç oranlarının araştırılması. ANKEM Derg 11 (1997).
26. **Roland RK, Mendes RE, Silbert S, Bolsoni AP, Sader HS :** In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams. Braz J Infect Dis 4: 226 (2000).
27. **Kuzucu Ç, Kabakçıoğlu M, Özışık A, Osmanoğlu Ezen F, Acar NS:** Nozokomiyal gram negatif bakterilerde genişletilmiş spektrumlu ve kromozomal beta-laktamaz varlığının saptanması. Flora 4:102 (1999).
28. **Vahaboğlu H:** Beta-laktamazlar ve hastane infeksiyonları. Hast İnfek Derg 2: 147 (1998).
29. **Özsoy MF, Öncül O, Yıldırım A, Pahsa A:** Genişletilmiş spektrumlu beta-laktamazlar: Klinik önemi ve getirdiği sorunlar. Flora 6: Ek 1 (2001).
30. **Akova M:** Beta-laktam direncinde bölgesel farklılıklar . “ Matsuhisa Inoue (ed): Beta-laktam Direncinde Önemli Konular ve Yanıtlar “ Birinci Net Care toplantısının Metinleri Monte Carlo , s12, Ekim 1999, Cambridge Medical Publications, UK (2001).
31. **Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J:** Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients : geographic patterns, epidemiological features and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis 32 (Suppl 2) :104 (2001).
32. **Marchandin H, Jean-Pierre H, De Champs C et al:** Production of a TEM-24 plasmid-mediated extended-spectrum beta-lactamase by a clinical isolate of Pseudomonas aeruginosa. Antimicrob Agents Chemother 44: 213 (2000).
33. **Afzal-Shah M, Woodford N, Livermore DM:** Characterization of OXA- 25, OXA-26, and OXA-27 , molecular class D beta-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 45: 583 (2001).
34. **Luzzaro F, Mantengoli E , Penilli M, Lombardi G, Orlandi V, Orsatti A, Amicosante G, Rossolini GM, Toniolo A:** Dynamics of a nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum beta-lactamase. J Clin Microbiol 39: 1865 (2001).
35. **Naas T, Poirel L, Kavim A, Nordmann P:** Molecular characterization of In50, a class 1 integron encoding the gene for the extended-spectrum beta-lactamase VEB-1 in Pseudomonas aeruginosa. FEMS Microbiol Lett 176: 411 (1999).

36. Gülay Z: Antibiyotiklere direnç mekanizmaları ve çözüm önerileri : beta-laktamlara ve karbapenemlere direnç. Hast İnfeksi Derg 5 : 210 (2001).

37. Germeyan H, Bozok Johansson C, Çelik C : Çeşitli klinik örneklerden izole edilen *Pseudomonas aeruginosa*

suşlarının meropenem, imipenem ve siprofloksasin duyarlılığı. ANKEM Derg 9 :126 (1995).

38. Yıldırım Güvenç S, Sarpel C, Akdemir Ş: Yoğun bakım hastalarında çeşitli örneklerden izole edilen gram negatif çomaklarda karbapenem direnci. ANKEM Derg 12: 132 (1998).